Company news

GSK plc news in 2026

GSK plc's news releases, calls and decks from 2026, newest first.

View company

Q3 2026 US dollar translation

October 28, 2026

GSK delivers strong Q3 performance and continued momentum

October 28, 2026

3rd Quarter Results

October 28, 2026

Ris-Rez positive Ph 3 osteosarcoma data in China

October 26, 2026

Director/PDMR Shareholding

October 26, 2026

Jemperli data show 76% complete response rate

October 26, 2026

Positive Mo-Rez Phase Ib data in ovarian cancer

October 26, 2026

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

October 23, 2026

US FDA approves Hibsago for chronic hepatitis B

October 21, 2026

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)

October 20, 2026

Jemperli approved in MSI-H/dMMR rectal cancer

October 19, 2026

Ris-Rez positive early data in lung cancer

October 19, 2026

GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer

October 18, 2026

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

October 16, 2026

Director/PDMR Shareholding

October 15, 2026

Director/PDMR Shareholding

October 14, 2026

Director/PDMR Shareholding

October 13, 2026

Director/PDMR Shareholding

October 12, 2026

Wendy Becker CBE - New Directorship

October 8, 2026

Admission to Trading

October 6, 2026

Total Voting Rights

October 1, 2026

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

September 15, 2026

GSK to acquire T cell-engager for multiple myeloma

September 15, 2026

Ris-Rez Positive Ph 3 OS Lung Cancer Data in China

September 14, 2026

Jideytro positive data for ROS1-positive NSCLC

September 14, 2026

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

September 13, 2026

Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China

September 12, 2026

Japan approval of Shingrix in a prefilled syringe

September 10, 2026

mRNA flu vaccine candidate to advance to phase III

September 1, 2026

GSK appoints Tina Graves as President & General Manager, Canada

August 26, 2026

Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

August 24, 2026

First global approval for Hibsago in Japan

August 24, 2026

US FDA to review Jemperli for rectal cancer

August 24, 2026

GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma

August 18, 2026

Nucala (mepolizumab) receives a positive reimbursement recommendation from CDA-AMC for adults with chronic obstructive pulmonary disease (COPD)

August 18, 2026

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

July 29, 2026

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

July 28, 2026

New GSK flagship R&D centre in Cambridge

July 28, 2026

New survey reveals Canadians underestimate chronic hepatitis B and its link to liver cancer

July 28, 2026

Hansoh positive 2nd Phase III results for Riz-Rez

July 28, 2026

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

July 27, 2026

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada

July 24, 2026

GSK plc - Jideytro approved in the US for previously treated ROS1-positive non-small cell lung cancer

July 23, 2026

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

July 22, 2026

Jideytro approved in US for certain lung cancers

July 22, 2026

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

July 21, 2026

European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds

July 20, 2026

Bexsero 1-dose booster EMA file acceptance

July 20, 2026

Audit tender conclusion

July 17, 2026

Older news releases →

Calls in 2026

Decks in 2026